These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

118 related items for PubMed ID: 7541424

  • 1. Chimeric horse/human recombinant C9 proteins identify the amino acid sequence in horse C9 responsible for restriction of hemolysis.
    Tomlinson S, Wang Y, Ueda E, Esser AF.
    J Immunol; 1995 Jul 01; 155(1):436-44. PubMed ID: 7541424
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Role of a disulfide-bonded peptide loop within human complement C9 in the species-selectivity of complement inhibitor CD59.
    Husler T, Lockert DH, Sims PJ.
    Biochemistry; 1996 Mar 12; 35(10):3263-9. PubMed ID: 8605162
    [Abstract] [Full Text] [Related]

  • 5. Characterization of rabbit complement component C8. Functional evidence for the species-selective recognition of C8 alpha by homologous restriction factor (CD59).
    White RV, Kaufman KM, Letson CS, Platteborze PL, Sodetz JM.
    J Immunol; 1994 Mar 01; 152(5):2501-8. PubMed ID: 7510745
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Interactions of soluble CD59 with the terminal complement complexes. CD59 and C9 compete for a nascent epitope on C8.
    Lehto T, Meri S.
    J Immunol; 1993 Nov 01; 151(9):4941-9. PubMed ID: 7691959
    [Abstract] [Full Text] [Related]

  • 9. Recombinant soluble CD59 inhibits reactive haemolysis with complement.
    Sugita Y, Ito K, Shiozuka K, Suzuki H, Gushima H, Tomita M, Masuho Y.
    Immunology; 1994 May 01; 82(1):34-41. PubMed ID: 7519172
    [Abstract] [Full Text] [Related]

  • 10. Mapping the regions of the complement inhibitor CD59 responsible for its species selective activity.
    Yu J, Dong S, Rushmere NK, Morgan BP, Abagyan R, Tomlinson S.
    Biochemistry; 1997 Aug 05; 36(31):9423-8. PubMed ID: 9235986
    [Abstract] [Full Text] [Related]

  • 11. Chimeras of human complement C9 reveal the site recognized by complement regulatory protein CD59.
    Hüsler T, Lockert DH, Kaufman KM, Sodetz JM, Sims PJ.
    J Biol Chem; 1995 Feb 24; 270(8):3483-6. PubMed ID: 7533152
    [Abstract] [Full Text] [Related]

  • 12. Identification of the discontinuous epitope in human complement protein C9 recognized by anti-melittin antibodies.
    Laine RO, Esser AF.
    J Immunol; 1989 Jul 15; 143(2):553-7. PubMed ID: 2472443
    [Abstract] [Full Text] [Related]

  • 13. Mapping of the complement C9 binding domain in paramyosin of the blood fluke Schistosoma mansoni.
    Deng J, Gold D, LoVerde PT, Fishelson Z.
    Int J Parasitol; 2007 Jan 15; 37(1):67-75. PubMed ID: 17123534
    [Abstract] [Full Text] [Related]

  • 14. The role of the C9b domain in the binding of C9 molecules to EAC1-8 defined by monoclonal antibodies to C9.
    Yoden A, Moriyama T, Inoue K, Inai S.
    J Immunol; 1988 Apr 01; 140(7):2317-21. PubMed ID: 3351301
    [Abstract] [Full Text] [Related]

  • 15. Horse cytokine/IgG fusion proteins--mammalian expression of biologically active cytokines and a system to verify antibody specificity to equine cytokines.
    Wagner B, Robeson J, McCracken M, Wattrang E, Antczak DF.
    Vet Immunol Immunopathol; 2005 May 01; 105(1-2):1-14. PubMed ID: 15797470
    [Abstract] [Full Text] [Related]

  • 16. Altered glycosylation and selected mutation in recombinant human complement component C9: effects on haemolytic activity.
    Taylor KM, Morgan BP, Campbell AK.
    Immunology; 1994 Nov 01; 83(3):501-6. PubMed ID: 7835977
    [Abstract] [Full Text] [Related]

  • 17. Identity of a peptide domain of human C9 that is bound by the cell-surface complement inhibitor, CD59.
    Chang CP, Hüsler T, Zhao J, Wiedmer T, Sims PJ.
    J Biol Chem; 1994 Oct 21; 269(42):26424-30. PubMed ID: 7523406
    [Abstract] [Full Text] [Related]

  • 18. Clusterin, the human apolipoprotein and complement inhibitor, binds to complement C7, C8 beta, and the b domain of C9.
    Tschopp J, Chonn A, Hertig S, French LE.
    J Immunol; 1993 Aug 15; 151(4):2159-65. PubMed ID: 8345200
    [Abstract] [Full Text] [Related]

  • 19. Regulation of the membrane attack complex of complement. Evidence that C8 gamma is not the target of homologous restriction factors.
    Davé SJ, Sodetz JM.
    J Immunol; 1990 Apr 15; 144(8):3087-90. PubMed ID: 2324496
    [Abstract] [Full Text] [Related]

  • 20. Functional studies of the MACPF domain of human complement protein C8alpha reveal sites for simultaneous binding of C8beta, C8gamma, and C9.
    Slade DJ, Chiswell B, Sodetz JM.
    Biochemistry; 2006 Apr 25; 45(16):5290-6. PubMed ID: 16618117
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.